Cited by 500Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Open access

Kodumudi, Krithika N., Woan, Karrune, Gilvary, Danielle L., Sahakian, Eva, Wei, Sheng, Djeu, Julie Y.·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-0733PMC PMC3874864

Open this paper in CoChat — free account

Abstract

Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effect of chemotherapeutic agents on MDSCs. Agents that inhibit MDSCs may be useful in the treatment of patients with various cancers. Experimental Design: We investigated the in vivo effects of docetaxel on immune function in 4T1-Neu mammary tumor-bearing mice to examine if a favorable immunomodulatory effect accompanies tumor suppression. Primary focus was on the differentiation status of MDSCs and their ability to modulate T-cell responses. Results: Docetaxel administration significantly inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC proportion in the spleen. The treatment also selectively increased CTL responses. Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA323-339 showed OT-II–specific CD4 activation and expansion in vitro. In characterizing the phenotype of MDSCs for M1 (CCR7) and M2 [mannose receptor (CD206)] markers, MDSCs from untreated tumor bearers were primarily MR+ with few CCR7+ cells. Docetaxel treatment polarized MDSCs toward an M1-like phenotype, resulting in 40% of MDSCs expressing CCR7 in vivo and in vitro, and macrophage differentiation markers such as MHC class II, CD11c, and CD86 were upregulated. Interestingly, docetaxel induced cell death selectively in MR+ MDSCs while sparing the M1-like phenotype. Finally, inhibition of signal transducer and activator of transcription 3 may in part be responsible for the observed results. Conclusions: These findings suggest potential clinical benefit for the addition of docetaxel to current immunotherapeutic protocols. Clin Cancer Res; 16(18); 4583–94. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-0733

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,258
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Show all 42 references

Sorted by citations

Items 301–400 of 499

Glioblastoma immuno-endothelial multicellular microtissue as a 3D in vitro evaluation tool of anti-cancer nano-therapeutics
Martins, C., Pacheco, C., Moreira-Barbosa, C., Marques-Magalhães, Â., Dias, S., Araújo, M., Oliveira, M. J., & Sarmento, B. F. C. C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.024 · Cited by 21
Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials
Mineharu, Y., Castro, M. G., Lowenstein, P. R., Sakai, N., & Miyamoto, S. (2013) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra2013-0234 · Cited by 21
Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens
Xǔ, J., Tian, K., Zhang, H., Li, L., Liu, H., Liu, J., Zhang, Q., & Zheng, J. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1395285 · Cited by 21
Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
Qiu, Y., & Xu, J. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_10_19 · Cited by 21
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models
Kamoun, W. S., Dugast, A., Suchy, J. J., Grabow, S., Fulton, R. B., Sampson, J. F., Luus, L., Santiago, M. D. M. G., Koshkaryev, A., Sun, G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0414 · Cited by 21
A New Mechanism for Blocking Myeloid-Derived Suppressor Cells by CpG
Lechner, M. G., & Epstein, A. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0024 · Cited by 21
Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies
Nie, S.-C., Jing, Y., Lu, L., Ren, S.-S., Ji, G., & Xu, H.-C. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1690 · Cited by 22
Myeloid Derived Suppressor Cells
Fujimura, T., & Enk, A. (2016) · Springer eBooks · doi:10.1007/978-4-431-55855-2_11 · Cited by 19
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
Russo, A., Franchina, T., Ricciardi, G. R. R., Toscano, G., Schifano, S., Certo, G. L., Battaglia, A., Pantò, E., Fonti, M. S., & Adamo, V. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.007 · Cited by 19
Metronomic chemotherapy in non‑small cell lung cancer (Review)
Shu, Y., Weng, S., & Zheng, S. (2020) · Oncology Letters · doi:10.3892/ol.2020.12170 · Cited by 19
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
Kerrison, W. G. J., Lee, A. T. J., Thway, K., Jones, R. L., & Huang, P. H. (2022) · Biomedicines · doi:10.3390/biomedicines10030573 · Cited by 19
Dendritic cell vaccine of gliomas: challenges from bench to bed
Zheng, Y., Ma, X., Feng, S., Zhu, H., Chen, X., Yu, X., Shu, K., & Zhang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259562 · Cited by 19
Ganoderma lucidum spores-derived particulate β-glucan treatment improves antitumor response by regulating myeloid-derived suppressor cells in triple-negative breast cancer
Bu, Y., Liu, Q., Shang, Y., Zhao, Z., Sun, H., Chen, F., Ma, Q., Song, J., Cui, L., Sun, E., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131949 · Cited by 20
PM01183 Inhibits Myeloid-Derived Suppressor Cells In Vitro and In Vivo
Kuroda, H., Mabuchi, S., Kozasa, K., Yokoi, E., Matsumoto, Y., Komura, N., Kawano, M., Hashimoto, K., Sawada, K., & Kimura, T. (2017) · Immunotherapy · doi:10.2217/imt-2017-0046 · Cited by 19
Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer
Lao, L., Fan, S., & Song, E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_16 · Cited by 19
A Strategy for Suppressing Macrophage-mediated Rejection in Xenotransplantation
Maeda, A., Lo, P., Sakai, R., Noguchi, Y., Kodama, T., Yoneyama, T., Toyama, C., Wang, H., Esquivel, E., Jiaravuthisan, P., et al. (2019) · Transplantation · doi:10.1097/tp.0000000000003024 · Cited by 19
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells
Otsuka, K., Mitsuhashi, A., Goto, H., Hanibuchi, M., Koyama, K., Ogawa, H., Ogino, H., Saijo, A., Kozai, H., Yoneda, H., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.023 · Cited by 19
Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells
Lee, J.-M., Shin, K., Koh, C., Song, B., Jeon, I., Park, M. H., Kim, B., Chung, Y., & Kang, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.031 · Cited by 19
Targeting the spectrum of immune checkpoints in prostate cancer
Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 19
Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss
Chen, K., Yang, J., Fan, H., Dai, Y., Wang, X., Chen, R., Liu, J., Meng, X., Wang, W., Li, G., et al. (2022) · Bone Research · doi:10.1038/s41413-022-00232-x · Cited by 18
Immunogenic chemotherapy: great potential for improving response rates
Huang, X., Ren, Q., Yang, L., Cui, D., Ma, C., Zheng, Y., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1308681 · Cited by 21
Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163+Arginase 1+M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma
Fujimura, T., Kambayashi, Y., Furudate, S., Kakizaki, A., & Aiba, S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/325412 · Cited by 18
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
Bronger, H. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1475-4335 · Cited by 19
α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response
Hahn, T., Jagadish, B., Mash, E. A., Garrison, K., & Akporiaye, E. T. (2011) · Breast Cancer Research · doi:10.1186/bcr2808 · Cited by 18
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells
Fernández, A., Oliver, L., Álvarez-Arzola, R., Hernández, A., Raymond, J., Fernandez, L. E., & Mesa, C. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-5 · Cited by 18
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
Stovgaard, E. S., Asleh, K., Riaz, N., Leung, S. C. Y., Gao, D., Nielsen, L. B., Lænkholm, A., Balslev, E., Jensen, M., Nielsen, D. L., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1924492 · Cited by 17
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti‐tumor properties of PEDF with various efficacy and toxicity
Jarvis, C., Nelius, T., Martinez‐Marin, D., Sennoune, S. R., & Filleur, S. (2018) · The Prostate · doi:10.1002/pros.23647 · Cited by 17
Yin-yang effect of tumour cells in breast cancer: from mechanism of crosstalk between tumour-associated macrophages and cancer-associated adipocytes.
Zhu, Z., Zhu, X., Yang, S., Guo, Z., Li, K., Ren, C., Zhou, Y., & Dou, J. (2020) · PubMed Central · Cited by 17
Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice
Hamilton, M. J., Banáth, J. P., Lam, V., LePard, N. E., Krystal, G., & Bennewith, K. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1125-0 · Cited by 17
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice
Mikyšková, R., Indrová, M., Štěpánek, I., Kanchev, I., Bieblová, J., Vosahlikova, S., Moserova, I. K., Truxová, I., Fucikova, J. P., Bartůňková, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1362528 · Cited by 17
Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy
Yin, W., Ma, S.-C., Dong, Z., Xu, M., & Mao, W. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310331 · Cited by 16
Exosomes as a drug delivery tool for cancer therapy: a new era for existing drugs and oncolytic viruses
Kakiuchi, Y., Kuroda, S., Kanaya, N., Kagawa, S., Tazawa, H., & Fujiwara, T. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2259102 · Cited by 16
Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes
Zhang, C., Li, F., Li, J., Xu, Y., Wang, L., & Zhang, Y. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.010 · Cited by 16
Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer
Gou, H., Zhou, L., Huang, J. M., & Chen, X.-C. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9219 · Cited by 16
The Evolving Landscape of Immunotherapy in Advanced Prostate Cancer
Patel, V. G., & Oh, W. K. (2019) · Immunotherapy · doi:10.2217/imt-2019-0019 · Cited by 16
PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death
Tham, M. J. R., Babak, M. V., & Ang, W. H. (2020) · Angewandte Chemie · doi:10.1002/ange.202008604 · Cited by 16
Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients
Yuan, L., Xu, B., Fan, H., YUAN, P., Zhao, P., & Suo, Z. H. (2015) · Neoplasma · doi:10.4149/neo_2015_029 · Cited by 16
Comparison of Immunosuppressive and Cytotoxic Cells in Angiosarcoma: Development of a Possible Supportive Therapy for Angiosarcoma
Kambayashi, Y., Fujimura, T., Furudate, S., Hashimoto, A., Haga, T., & Aiba, S. (2013) · Dermatology · doi:10.1159/000351316 · Cited by 16
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer
Liao, J. B., Swensen, R. E., Ovenell, K. J., Hitchcock-Bernhardt, K. M., Reichow, J. L., Apodaca, M. C., D’Amico, L., Childs, J. S., Higgins, D. M., Buening, B. J., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.01.008 · Cited by 16
Pilot study of WT1 peptide‑pulsed dendritic cell vaccination with docetaxel in esophageal cancer
Matsuda, T., Takeuchi, H., Sakurai, T., Mayanagi, S., Booka, E., Fujita, T., Higuchi, H., Taguchi, J., Hamamoto, Y., Takaishi, H., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8734 · Cited by 16
Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction
Álvarez-Arzola, R., Oliver, L., Valdés, A. F.-C., & Mesa, C. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.05.001 · Cited by 17
Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts
Maulhardt, H. A., Hylle, L., Frost, M., Tornio, A., Dafoe, S., Drummond, L., Quinn, D. I., Kamat, A. M., & diZerega, G. S. (2019) · Cancers · doi:10.3390/cancers11040577 · Cited by 17
Myeloid-Derived Suppressor Cells: Orchestrators of Tumor Immune Evasion and Therapeutic Vulnerabilities
Wang, Z., Du, X., Xing, X., Xie, W., Xin, H., & Liu, W. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0251 · Cited by 15
The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
Shi, M.-Y., Liu, H.-G., Chen, X.-H., Tian, Y., Chen, Z., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088886 · Cited by 15
Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors
Bravetti, G., Falvo, P., Talarico, G., Orecchioni, S., & Bertolini, F. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216441 · Cited by 16
Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy
Chen, J.-Y., Lin, P.-Y., Hong, W.-Z., Yang, P.-C., Chiang, S., Chang, H.-Y., Ke, T., Liang, J., Chen, W. T., Chao, K. S. C., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03692-8 · Cited by 18
Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model
Hu, Y., Liu, J., Cui, P., Liu, T., Piao, C., Xu, X., Zhang, Q., Xiao, M., Lu, Y., Liu, X., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.104036 · Cited by 16
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
Gaynor, N., Blanco, A., Madden, S. F., Moran, B., Fletcher, J. M., Kaukonen, D., Ramírez, J. S., Eustace, A. J., McDermott, M. S. J., Canonici, A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02375-y · Cited by 14
Myeloid cells as potential targets for immunotherapy in pediatric gliomas
Frederico, S. C., Sharma, N., Darling, C., Taori, S., Dubinsky, A. C., Zhang, X., Raphael, I., & Kohanbash, G. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1346493 · Cited by 14
Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer
Bos, T., Ratti, J. A., & Harada, H. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.676643 · Cited by 15
Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells
Jinushi, M., Yagita∥, H., Yoshiyama, H., & Tahara, H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.06.001 · Cited by 15
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
Shafique, M. R., Robinson, L. A., & Antonia, S. J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s148009 · Cited by 14
Norcantharidin promotes M1 macrophage polarization and suppresses colorectal cancer growth
Wei, X., Lu, S., Li, L., Gao, Y.-J., Wang, J., Xi, S.-Y., Ye, L.-Y. L., Shen, W., Wu, M., Duan, D. D., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01578-8 · Cited by 13
Perspectives on Immunotherapy in Prostate Cancer and Solid Tumors: Where Is the Future?
Snyder, A., Tepper, J. E., & Slovin, S. F. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.04.009 · Cited by 13
Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells
Kim, S., Ha, G., Kim, S., & Kang, C. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.857352 · Cited by 13
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study
Parikh, M., Pan, C.-X., Beckett, L. A., Li, Y., Robles, D., Aujla, P. K., & Lara, P. N. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.004 · Cited by 13
Astaxanthin Treatment Induces Maturation and Functional Change of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Jeong, S. M., & Kim, Y. (2020) · Antioxidants · doi:10.3390/antiox9040350 · Cited by 13
Current status and future of cancer vaccines: A bibliographic study
Yu, R., Zhao, F., Xu, Z., Zhang, G., Du, B., & Shu, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24404 · Cited by 12
DNA‐damaging drug‐induced apoptosis sensitized by N‐myc in neuroblastoma cells
Li, T., Wang, L., Ke, X., Gong, X., Wan, J., Hao, X., Xu, M., Xiang, Z., Cui, Z., & Cui, H. (2011) · Cell Biology International · doi:10.1042/cbi20110231 · Cited by 12
Chemotherapeutic targeting of myeloid-derived suppressor cells
Alizadeh, D., Katsanis, E., & Larmonier, N. (2014) · OncoImmunology · doi:10.4161/onci.27359 · Cited by 12
Prostate cancer vaccines
Michael, A., Relph, K., Annels, N. E., & Pandha, H. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.27 · Cited by 12
Metronomic Therapy in Oral Squamous Cell Carcinoma
Su, N.-W., & Chen, Y.-J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132818 · Cited by 12
Intermittent fasting suppressed splenic CD205+ G‐MDSC accumulation in a murine breast cancer model by attenuating cell trafficking and inducing apoptosis
Fu, C., Lu, Y., Zhang, Y., Yu, M., Ma, S., & Lyu, S. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2510 · Cited by 12
Intrinsic Modulation of Lymphocyte Function by Stromal Cell Network: Advance in Therapeutic Targeting of Cancer
Görgün, G., & Anderson, K. C. (2011) · Immunotherapy · doi:10.2217/imt.11.124 · Cited by 12
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma
Kim, S. C. H., Paget‐Bailly, S., Messager, M., Nguyen, T. H. T., Mathieu, P., Lamfichekh, N., Fein, F., Fratté, S., Cléau, D., Lakkis, Z., et al. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.06.395 · Cited by 12
Core–Satellite Nanoassembly Overcomes Spatial Heterogeneity of Dendric Cell Distribution in Pancreatic Tumors for Effective Chemoimmunotherapy
Chen, G., Li, B., Li, T., Lin, M., Zhong, H., Xie, X., Zhang, Q., Chen, Q., Meng, X., Xiao, Z., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c15444 · Cited by 11
The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring
Vergati, M., Schlom, J., & Tsang, K. Y. (2011) · BioMed Research International · doi:10.1155/2011/182413 · Cited by 11
Specific Depletion of Myeloid-Derived Suppressor Cells by the Chemotherapy Agent 5-Fluorouracil Enhances Protective Immune Response in Paracoccidioidomycosis
Preite, N. W., Kaminski, V. D. L., Borges, B. M., dos Santos, B. V., Calich, V. L. G., & Loures, F. V. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae350 · Cited by 10
Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy
Djeu, J. Y., & Wei, S. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18074 · Cited by 10
Self-citation
A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma
Ju, H., Wei, D., Wu, Y., Liu, Y., Ding, Q., Rui, M., Fan, Z., Yao, Y., Hu, J., & Ren, G. (2023) · MedComm · doi:10.1002/mco2.312 · Cited by 10
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
Wispelaere, W. D., Annibali, D., Tuyaerts, S., Lambrechts, D., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13092040 · Cited by 10
The Fabrication of Docetaxel-Containing Emulsion for Drug Release Kinetics and Lipid Peroxidation
Wu, Y., Wang, M., Li, Y., Xia, H., Cheng, Y., Liu, C., Xia, Y., Wang, Y., Yue, Y., Cheng, X., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101993 · Cited by 10
Cell-mediated barriers in cancer immunosurveillance
Rezaie, J., Chodari, L., Mohammadpour-Asl, S., Jafari, A., & Niknam, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122528 · Cited by 9
Engineered nanomicelles targeting proliferation and angiogenesis inhibit tumour progression by impairing the synthesis of ceramide-1-phosphate
Yadav, P., Rana, K., Chakraborty, R., Khan, A., Mehta, D., Jain, D., Aggarwal, B., Jha, S. K., Dasgupta, U., & Bajaj, A. (2024) · Nanoscale · doi:10.1039/d3nr04806c · Cited by 9
Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
Silva-Romeiro, S., Flores-Campos, R., Sánchez-León, M. L., Sánchez‐Margalet, V., & de la Cruz‐Merino, L. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485642 · Cited by 10
It takes two to tango: the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy
Sheban, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183578 · Cited by 9
Engineered nanomicelles inhibit the tumour progression via abrogating the prostaglandin-mediated immunosuppression
Yadav, P., Rana, K., Nardini, V., Khan, A., Pani, T., Kar, A., Jain, D., Chakraborty, R., Singh, R., Jha, S. K., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.009 · Cited by 9
Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?
Liu, Q., Wu, P., Lei, J., Bai, P., Zhong, P., Yang, M., & Wei, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135541 · Cited by 9
Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
Slovin, S. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00043 · Cited by 9
Tumor‑associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review)
Жукова, О. В., Kovaleva, T. F., Архипова, Е. В., Ryabov, S. A., & Mukhina, I. V. (2020) · Biomedical Reports · doi:10.3892/br.2020.1354 · Cited by 9
The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
Kang, D. H., Choi, S., Sun, P., Chung, C., Park, D., Lee, S., Koh, J. S., Kim, Y., & Lee, J. E. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14568 · Cited by 9
The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC)
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00001-7 · Cited by 8
It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241208 · Cited by 8
A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy
Li, S., Chu, X., Ye, L., Ni, J., & Zhu, Z. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-512 · Cited by 8
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
Viscardi, G., Vitiello, F., Servetto, A., Gristina, V., Pizzutilo, E. G., Canciello, M. A., Medusa, P. M., Salomone, F., Guida, G. D., Mollica, M., et al. (2022) · Cancers · doi:10.3390/cancers14235810 · Cited by 8
Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
Chìn, K., Yamamoto, S., Takahashi, M., Kadowaki, S., Kubota, Y., Amanuma, Y., Okada, M., Kanda, M., Kimura, Y., Nogi, Y., et al. (2022) · Esophagus · doi:10.1007/s10388-022-00972-z · Cited by 8
A Tick Cysteine Protease Inhibitor RHcyst-1 Exhibits Antitumor Potential
Wei, N., Lin, Z., Xu, Z., Cao, J., Zhou, Y., Zhang, H., Gong, H., Zhou, J., & Li, G. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489645 · Cited by 8
Tumor‐Targeted Superantigens
Hedlund, G., Forsberg, G., Nederman, T., Sundstedt, A., Dahlberg, L., Tiensuu, M., & Nilsson, M. F. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch24 · Cited by 8
Immunogenen Zelltod induzierende Metallkomplexe für die Krebstherapie
Zhang, L., Montesdeoca, N., Karges, J., & Xiao, H. (2023) · Angewandte Chemie · doi:10.1002/ange.202300662 · Cited by 7
Docetaxel-Loaded Electrospun Nanofibrous Mats for Local Chemotherapy Targeting Positive Surgical Margins in Prostate Cancer
Li, X., Yuan, K., Yin, Y., Tian, Y., Guo, Z., Qin, Z., & Zeng, X. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01440 · Cited by 7
Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies
Nakashima, K., Umeda, Y., Demura, Y., Sonoda, T., Tada, T., Yamaguchi, M., Anzai, M., Kadowaki, M., Oi, M., Honjo, C., et al. (2024) · Oncology · doi:10.1159/000535994 · Cited by 7
Targeting the breast tumor microenvironment by plant-derived products and their nanoformulations
Zhang, H., & Li, Y. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105432 · Cited by 7
Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies
Porter, L. H., Harrison, S., Risbridger, G. P., Lister, N. L., & Taylor, R. A. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106571 · Cited by 7
Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol
Syn, N. L. X., Roudi, R., Wang, L. Z., Wang, L., Loh, M. C. S., Huang, Y., Ou, S. I., Soong, R., Drilon, A. E. D. C., & Wee, I. J. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013009 · Cited by 7
Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
Kaplon, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835502 · Cited by 6
Copper peroxide-triggered reactive nitrogen effectively enhanced synergistic chemodynamic-immunotherapy
Zhu, Y., Wang, N., Zhang, H.-B., Ling, J., Omer, A. M., Yang, G., Ouyang, X., & Mei, L. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.138301 · Cited by 6
Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer
Yamada, Y., Yamamoto, T., Tsutsumi, C., Matsumoto, T., Noguchi, S., Shimada, Y., Nakata, K., Ohuchida, K., Nakamura, M., & Oda, Y. (2024) · Cancer Science · doi:10.1111/cas.16060 · Cited by 6
Myeloid Derived Suppressor Cells: Subsets, Expansion, and Role in Cancer Progression
Abastado, J., & Zhi, L. (2012) · InTech eBooks · doi:10.5772/36409 · Cited by 6
Quelle place pour les associations de l’immunothérapie à la chimiothérapie ou de plusieurs immunothérapies ?
Douchet, G., & Aspeslagh, S. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.03.008 · Cited by 6
Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma
Khurana, A., Armand, P. A., & Ansell, S. M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1709832 · Cited by 6

Authors: Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y.
Affiliations: Moffitt Cancer Center (US)
Authors' Affiliation: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida
Corresponding author: Djeu, Julie Y.
ORCID: Kodumudi, Krithika N.
Woan, Karrune
Sahakian, Eva
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-09-14
Volume: 16
Issue: 18
Pages: 4583-4594
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-0733
PMC: PMC3874864
OpenAlex: W2143994426
Cited by: 500
References: 42
Citations by year: 2026: 6 · 2025: 14 · 2024: 33 · 2023: 32 · 2022: 37 · 2021: 39 · 2020: 39 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 42 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 22
FWCI: 10.74
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (T32CA115308)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: docetaxel, myeloid-derived suppressor cells, tumor immunosuppression, CTL response, CD4+ T cell activation, CD206, CCR7, macrophage differentiation, STAT3 signaling, tumor-bearing mice
MeSH terms: Docetaxel, Animals, Antineoplastic Agents, Cell Differentiation, Cytotoxicity, Immunologic, Female, Immune Tolerance, Immunosuppressive Agents, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Transplantation, Neoplasms, T-Lymphocytes, Myeloid Cells, Taxoids, Cell Line, Tumor, Mice, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks